The 2018 Miami Breast Cancer Conference (March 8-11) offered insight into the optimal multidisciplinary management of patients with breast cancer.


A recent survey found that 90% of patients treated with radiation therapy for breast cancer found their experiences to be less “scary” than anticipated.
Breast cancer surgeons play a big role in deciding whether women with early-stage breast cancer undergo a controversial operation to have both breasts removed, even when cancer is found in only one.
Patients with breast cancer who take opioids to manage their pain are less likely to adhere to adjuvant therapy, resulting in a higher risk of death.
Omitting radiation after lumpectomy for pure ductal carcinoma in situ does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.

Research in Review

Use of the 21-gene recurrence score (RS) assay is helping clinicians and patients decide which treatments are best for them, according to a large-scale survey of more than 3000 women treated for breast cancer.
Adjuvant endocrine therapy with tamoxifen or aromatase inhibitors may reduce the risk for contralateral breast cancer (CBC) in women with invasive breast cancer.
Response-guided neoadjuvant chemotherapy is more cost effective than conventional NACT for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Perceived barriers to treatment may predict patient nonadherence to aromatase inhibitors for women with early-stage, estrogen receptor-positive breast cancer.
Subscribe to Breast Cancer